Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMP2016)

Drug Name

TA1-RTA Drug Info

Synonyms

CHEMBL8197; 8-methyl-8-azabicyclo[3.2.1]oct-3-yl 1H-indole-3-carboxylate; 89565-68-4; 124583-47-7; (8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 1H-indole-3-carboxylate; 1H-Indole-3-carboxylic acid, 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester; 1H-Indole-3-carboxylic acid, 8-methyl-8-azabicyclo(3.2.1)oct-3-yl ester, endo-; NCGC00015984-03; ACMC-20mr3z; ACMC-20bn7f; Enamine_001310; Biomol-NT_000158; AC1L1KP5; REGID_for_CID_5595; Oprea1_655173; Lopac0_001253; Oprea1_462281; MLS000055682; SCHEMBL463128; AC1Q625H; SCHEMBL8946882

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 5595
ChEBI ID: CHEBI:91913
CAS Number: CAS 89565-68-4
TTD Drug ID: DMP2016

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Erbb2 tyrosine kinase receptor (HER2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[2]
Dacomitinib	DMOH8VY	Non-small-cell lung cancer	2C25.Y	Approved	[3]
BIBW 2992	DMTKD7Q	Non-small-cell lung cancer	2C25.Y	Approved	[4]
Merimepodib	DM0HS92	Breast cancer	2C60-2C65	Approved	[5]
NERATINIB MALEATE	DMEDU7B	HER2/NEU overexpressing breast cancer	2C60-2C65	Approved	[6]
Margetuximab	DMKEY6S	HER2-positive breast cancer	2C60-2C65	Approved	[7]
Trastuzumab	DMZQOUX	Breast cancer	2C60-2C65	Approved	[8]
Tucatinib	DMBESUA	HER2-positive breast cancer	2C60-2C65	Approved	[9]
Pertuzumab	DMHJV0X	Adrenal gland neoplasm		Approved	[10]
Masoprocol	DMMVNZ0	Prostate cancer	2C82.0	Approved	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Erbb2 tyrosine kinase receptor (HER2)	TT6EO5L	ERBB2_HUMAN	Binder	[1]

------------------------------------------------------------------------------------

References

1	Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2. Clin Cancer Res.2000 Aug;6(8):3334-41.
2	Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7422).
4	Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
5	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
6	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
7	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
8	Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study. Melanoma Res. 2004 Jun;14(3):207-10.
9	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
10	Clinical pipeline report, company report or official report of Roche (2009).
11	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.